ClinicalTrials.gg
CompletedNCT03486899FALCON 1Updated Sep 9, 2022Results posted

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

A Phase 2 interventional study of BMS-986036 and Placebo in Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis, sponsored by Bristol-Myers Squibb. Completed at 89 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 231 studies in Liver Cirrhosis with a site in United States — 45 open to participants now, 63 under way, 3 of them phase 3. Liver Cirrhosis · United States.

Enrollment
39th of 166
197 · median 55
Started
2018
with 20 others
Phase 2
58 of 231
13 open now
Registered
91st of 231
by date
Lead sponsor
5 of 231
Bristol-Myers Squibb

Among the 231 studies in Liver Cirrhosis with a site in United States, this one is the 39th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2018, is one of 58 in phase 2, and was the 91st registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

45 of the 231 studies in Liver Cirrhosis with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Liver Cirrhosis with a site in United States, or all of them as a file.
02

Study summary

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

03

Conditions studied

  • Liver Fibrosis
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver performed within 6 months (26 weeks) prior to the screening period. If historical biopsy is not available, a liver biopsy will be performed during the screening period. Biopsy must be consistent with NASH, with: a) a score of at least 1 for each NAS component (steatosis, lobular inflammation, and ballooning), as assessed by the central reader, and b) stage 3 liver fibrosis according to the NASH CRN classification, as assessed by the central reader
  • Participants taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 weeks for statins) prior to and during the screening period
  • Participants taking vitamin E at doses greater than or equal to (>=) 800 IU/day must have been on stable doses for at least 6 months (26 weeks) prior to and during the Screening Period. Vitamin E treatment (>=800 IU/day) must not have been initiated after the qualifying liver biopsy was performed.

Exclusion criteria

Exclusion Criteria:

  • Other causes of liver disease (e.g., alcoholic liver disease, virus infection, chronic virus [HCV] infection, hepatitis, drug-induced hepatotoxicity, Wilson disease, α-1-antitrypsin deficiency, iron overload, and hemochromatosis); participants with HCV sustained viral response (undetectable HCV RNA) for at least 2 years prior to confirming study eligibility may be eligible
  • Current or past history of hepatocellular carcinoma (HCC)
  • Past or current evidence of hepatic decompensation (e.g., ascites, variceal bleeding, hepatic encephalopathy and/or spontaneous bacterial peritonitis) or liver transplantation

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    BMS-986036 Dose Level 1

    Administered by subcutaneous injection.

    Drug: BMS-986036

  • Experimental
    BMS-986036 Dose Level 2

    Administered by subcutaneous injection.

    Drug: BMS-986036

  • Experimental
    BMS-986036 Dose Level 3

    Administered by subcutaneous injection.

    Drug: BMS-986036

  • Placebo comparator
    Placebo

    Administered by subcutaneous injection.

    Other: Placebo

Interventions

  • Specified dose on specified days.

    Also known as: Pegbelfermin

  • OtherPlacebo

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24

    The percentage of participants who achieved a ≥1-stage improvement in fibrosis without worsening of NASH or NASH improvement with no worsening of fibrosis at week 24 in liver biopsy. Improvement in fibrosis is defined by the NASH Clinical Research Network (CRN) Fibrosis Score. Improvement in NASH is defined by a ≥2-stage decrease in the nonalcoholic fatty liver disease activity score (NAS). Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) by ≥1 point. Worsening of fibrosis is defined as an increase of fibrosis by ≥1 point as determined by the NASH CRN Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

Secondary outcomes

  1. The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24

    An improvement in fibrosis is defined as a decrease of ≥ 1-stage in the NASH CRN Fibrosis Score at week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

  2. The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24

    An improvement in Ishak fibrosis is defined as a decrease of fibrosis by ≥ 1-stage in the Ishak fibrosis score at week 24 in liver biopsy. ISHAKs uses a 0-6 scale: 1: centrilobular pericellular fibrosis, 2: centrilobular and periportal fibrosis, 3: bridging fibrosis (few bridges), 4: bridging fibrosis (many bridges), 5: early or incomplete cirrhosis, 6: established or advanced cirrhosis.

    Time frame: From first dose to 24 weeks after first dose

  3. The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24

    An improvement in CPA is defined as any decrease in CPA at week 24 in liver biopsy.

    Time frame: From first dose to 24 weeks after first dose

  4. The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24

    The percentage of participants with NASH resolution without worsening of fibrosis at week 24 in liver biopsy. NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1. Worsening of fibrosis is defined as an increase of fibrosis by ≥ 1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2). NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

  5. The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 24

    NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1 at week 24 in liver biopsy. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2).

    Time frame: From first dose to 24 weeks after first dose

  6. The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 24

    The percentage of participants with NASH improvement without worsening of fibrosis at week 24 in liver biopsy. NASH improvement defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥2 points with contribution from \>1 NAS component. Worsening of fibrosis is defined as an increase of ≥1-point in the NASH Clinical Research Network (CRN) Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

  7. The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 24

    An improvement in fibrosis is defined as a decrease of fibrosis by ≥1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score at week 24 in liver biopsy. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease activity score (NAS) by ≥ 1-stage. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

  8. The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 24

    The percentage of participants with NASH improvement at week 24 in liver biopsy. NASH improvement is defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points with contribution from \> 1 NAS component. The NASH CRN system assesses liver biopsies for degree of steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4). The 3 categories are added together in an unweighted fashion to determine the NAS, which ranges from 0 to 8.

    Time frame: From first dose to 24 weeks after first dose

  9. The Percentage of Participants With Progression to Cirrhosis at Week 24

    Progression to cirrhosis is defined by the nonalcoholic steatohepatitis clinical research network (NASH CRN) Fibrosis Stage 4 at Week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: From first dose to 24 weeks after first dose

07

Results

Posted Sep 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
Started49504949
Completed41394139
Not completed811810
Withdrew: Lost to follow-up4143
Withdrew: Death1001
Withdrew: Adverse event0202
Withdrew: Withdrawal by subject3743
Withdrew: Other reasons0101

Outcome measures

PrimaryThe Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24

The percentage of participants who achieved a ≥1-stage improvement in fibrosis without worsening of NASH or NASH improvement with no worsening of fibrosis at week 24 in liver biopsy. Improvement in fibrosis is defined by the NASH Clinical Research Network (CRN) Fibrosis Score. Improvement in NASH is defined by a ≥2-stage decrease in the nonalcoholic fatty liver disease activity score (NAS). Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) by ≥1 point. Worsening of fibrosis is defined as an increase of fibrosis by ≥1 point as determined by the NASH CRN Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 2430.6 (0.88 to 8.52)24.0 (0.61 to 6.27)26.5 (0.71 to 7.10)14.3 (NA to NA)
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.055 · Odds ratio (or): 2.65 · 95% CI 0.88 to 8.52
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.245 · Odds ratio (or): 1.89 · 95% CI 0.61 to 6.27
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.129 · Odds ratio (or): 2.17 · 95% CI 0.71 to 7.10
SecondaryThe Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24

An improvement in fibrosis is defined as a decrease of ≥ 1-stage in the NASH CRN Fibrosis Score at week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants Who Achieved an Improvement in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Score at Week 2416.314.020.48.2
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.214 · Odds ratio (or): 2.20 · 95% CI 0.53 to 10.64
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.381 · Odds ratio (or): 1.83 · 95% CI 0.43 to 9.10
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.079 · Odds ratio (or): 2.88 · 95% CI 0.75 to 13.48
SecondaryThe Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24

An improvement in Ishak fibrosis is defined as a decrease of fibrosis by ≥ 1-stage in the Ishak fibrosis score at week 24 in liver biopsy. ISHAKs uses a 0-6 scale: 1: centrilobular pericellular fibrosis, 2: centrilobular and periportal fibrosis, 3: bridging fibrosis (few bridges), 4: bridging fibrosis (many bridges), 5: early or incomplete cirrhosis, 6: established or advanced cirrhosis.

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 2422.416.026.512.2
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.180 · Odds ratio (or): 2.07 · 95% CI 0.63 to 7.47
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.612 · Odds ratio (or): 1.37 · 95% CI 0.38 to 5.20
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.079 · Odds ratio (or): 2.59 · 95% CI 0.81 to 9.10
SecondaryThe Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24

An improvement in CPA is defined as any decrease in CPA at week 24 in liver biopsy.

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 2442.953.555.865.9
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.038 · Odds ratio (or): 0.39 · 95% CI 0.15 to 1.03
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.256 · Odds ratio (or): 0.60 · 95% CI 0.22 to 1.57
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.296 · Odds ratio (or): 0.65 · 95% CI 0.25 to 1.73
SecondaryThe Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24

The percentage of participants with NASH resolution without worsening of fibrosis at week 24 in liver biopsy. NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1. Worsening of fibrosis is defined as an increase of fibrosis by ≥ 1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2). NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage Participants
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 24
Percentage ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 248.24.02.06.1
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.718 · Odds ratio (or): 1.36 · 95% CI 0.22 to 9.80
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.632 · Odds ratio (or): 0.64 · 95% CI 0.05 to 5.87
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.293 · Odds ratio (or): 0.32 · 95% CI 0.01 to 4.19
SecondaryThe Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 24

NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1 at week 24 in liver biopsy. Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade \<2).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 248.24.02.06.1
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.718 · Odds ratio (or): 1.36 · 95% CI 0.22 to 9.80
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.632 · Odds ratio (or): 0.64 · 95% CI 0.05 to 5.87
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.293 · Odds ratio (or): 0.32 · 95% CI 0.01 to 4.19
SecondaryThe Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 24

The percentage of participants with NASH improvement without worsening of fibrosis at week 24 in liver biopsy. NASH improvement defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥2 points with contribution from \>1 NAS component. Worsening of fibrosis is defined as an increase of ≥1-point in the NASH Clinical Research Network (CRN) Fibrosis Score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement Without Worsening of Fibrosis at Week 2422.414.016.310.2
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.101 · Odds ratio (or): 2.55 · 95% CI 0.73 to 10.12
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.587 · Odds ratio (or): 1.43 · 95% CI 0.36 to 6.17
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.371 · Odds ratio (or): 1.72 · 95% CI 0.45 to 7.20
SecondaryThe Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 24

An improvement in fibrosis is defined as a decrease of fibrosis by ≥1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score at week 24 in liver biopsy. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease activity score (NAS) by ≥ 1-stage. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 2416.314.016.38.2
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.214 · Odds ratio (or): 2.20 · 95% CI 0.53 to 10.64
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.381 · Odds ratio (or): 1.83 · 95% CI 0.43 to 9.10
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.214 · Odds ratio (or): 2.20 · 95% CI 0.53 to 10.64
SecondaryThe Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 24

The percentage of participants with NASH improvement at week 24 in liver biopsy. NASH improvement is defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points with contribution from \> 1 NAS component. The NASH CRN system assesses liver biopsies for degree of steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4). The 3 categories are added together in an unweighted fashion to determine the NAS, which ranges from 0 to 8.

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 2424.518.016.310.2
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.060 · Odds ratio (or): 2.85 · 95% CI 0.83 to 11.21
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.276 · Odds ratio (or): 1.93 · 95% CI 0.53 to 7.92
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.371 · Odds ratio (or): 1.72 · 95% CI 0.45 to 7.20
SecondaryThe Percentage of Participants With Progression to Cirrhosis at Week 24

Progression to cirrhosis is defined by the nonalcoholic steatohepatitis clinical research network (NASH CRN) Fibrosis Stage 4 at Week 24 in liver biopsy. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
From first dose to 24 weeks after first dose
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Progression to Cirrhosis at Week 24
Percentage of ParticipantsBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlacebo
The Percentage of Participants With Progression to Cirrhosis at Week 2430.622.028.620.4
Statistical analysis
  • BMS-986036 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.242 · Odds ratio (or): 1.72 · 95% CI 0.62 to 4.87
  • BMS-986036 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.803 · Odds ratio (or): 1.10 · 95% CI 0.37 to 3.26
  • BMS-986036 40 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.350 · Odds ratio (or): 1.56 · 95% CI 0.56 to 4.46

Adverse events

Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 35 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 52 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986036 10 mg1/49 (2%)3/49 (6.1%)36/49 (73.5%)
BMS-986036 20 mg0/50 (0%)7/50 (14%)38/50 (76%)
BMS-986036 40 mg0/49 (0%)6/49 (12.2%)39/49 (79.6%)
BMS-986036 Placebo1/49 (2%)9/49 (18.4%)33/49 (67.3%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgBMS-986036 Placebo
Non-cardiac chest painGeneral disorders0/491/500/492/49
Coronary artery diseaseCardiac disorders0/490/500/491/49
Coronary artery occlusionCardiac disorders0/490/501/490/49
Abdominal pain upperGastrointestinal disorders0/490/501/490/49
Epiploic appendagitisGastrointestinal disorders1/490/500/490/49
CholecystitisHepatobiliary disorders0/491/501/490/49
COVID-19 pneumoniaInfections and infestations0/491/501/490/49
Post procedural infectionInfections and infestations0/490/500/491/49
SepsisInfections and infestations0/490/500/491/49
Foot fractureInjury, poisoning and procedural complications0/490/500/491/49
Most frequent other events
Showing 10 of 40
Most frequent other events
EventBMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgBMS-986036 Placebo
NauseaGastrointestinal disorders13/4911/507/498/49
DiarrhoeaGastrointestinal disorders11/4910/5011/496/49
Injection site erythemaGeneral disorders2/493/507/490/49
FatigueGeneral disorders3/497/501/494/49
Abdominal pain upperGastrointestinal disorders6/492/503/492/49
Upper respiratory tract infectionInfections and infestations5/496/506/496/49
Urinary tract infectionInfections and infestations3/492/504/496/49
HeadacheNervous system disorders5/494/502/496/49
RashSkin and subcutaneous tissue disorders1/492/506/491/49
ArthralgiaMusculoskeletal and connective tissue disorders3/496/502/494/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlaceboTotal
Mean56.4 ± 9.5756.3 ± 10.0857.4 ± 10.5057.5 ± 8.0256.9 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlaceboTotal
Female29273129116
Male2023182081
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlaceboTotal
Hispanic or Latino1417151561
Not Hispanic or Latino34323433133
Unknown or Not Reported11013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS-986036 10 mgBMS-986036 20 mgBMS-986036 40 mgPlaceboTotal
American Indian or Alaska Native00000
Asian374418
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White43424241168
More than one race00000
Unknown or Not Reported31239
08

Study locations

89 sites
  • Local Institution - 0087
    Madison, Alabama 35758, United States
  • Local Institution - 0005
    Chandler, Arizona 85224, United States
  • Local Institution - 0088
    Phoenix, Arizona 85013, United States
  • Local Institution - 0001
    Phoenix, Arizona 85054, United States
  • The Institute for Liver Health - Tucson
    Tucson, Arizona 85712, United States
  • Local Institution - 0092
    Coronado, California 92118, United States
  • Kindred Medical Institute for Clinical Trials
    Corona, California 92879, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Local Institution - 0017
    Los Angeles, California 90036, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • GastroIntestinal Biosciences
    Los Angeles, California 90067-2015, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Local Institution - 0008
    Oakland, California 94611, United States
  • Local Institution - 0044
    Oxnard, California 93030, United States
  • Huntington Medical Research Institutes - HMRI Liver Center
    Pasadena, California 91105, United States
  • Local Institution - 0019
    Pasadena, California 91105, United States
  • Local Institution - 0074
    Redwood City, California 94063, United States
  • Local Institution - 0013
    Rialto, California 92377, United States
  • Local Institution - 0089
    San Clemente, California 92673, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Local Institution - 0068
    San Francisco, California 94115, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Local Institution - 0079
    Coral Gables, Florida 33134, United States
  • Top Medical Research
    Cutler Bay, Florida 33189, United States
  • Local Institution - 0100
    Gainesville, Florida 32610, United States
  • Clinical Research of Homestead
    Homestead, Florida 33030, United States
  • Local Institution - 0082
    Jacksonville, Florida 32224, United States
  • Local Institution - 0003
    Lakewood Ranch, Florida 34211, United States
  • Local Institution - 0002
    Miami, Florida 33136, United States
  • A+ Research
    Miami, Florida 33144, United States
  • IMIC Research
    Miami, Florida 33157, United States
  • Sensible Healthcare
    Ocoee, Florida 34761, United States
  • Local Institution - 0081
    Orlando, Florida 32806, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Local Institution - 0105
    Marietta, Georgia 30060, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Local Institution - 0027
    New Orleans, Louisiana 70121, United States
  • Local Institution - 0007
    Baltimore, Maryland 21202, United States
  • Local Institution - 0057
    Catonsville, Maryland 21228, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0063
    Chesterfield, Missouri 63005, United States
  • Saint Lukes Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • University at Buffalo
    Buffalo, New York 14203, United States
  • Local Institution - 0078
    Manhasset, New York 11030, United States
  • Local Institution - 0083
    New York, New York 10003, United States
  • Local Institution - 0038
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Local Institution - 0067
    Butner, North Carolina 27509-1626, United States
  • Local Institution - 0064
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0096
    Concord, North Carolina 28027, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0009
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0006
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0047
    Germantown, Tennessee 38138, United States
  • Local Institution - 0041
    Hermitage, Tennessee 37076, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5280, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Local Institution - 0066
    Austin, Texas 78757, United States
  • Local Institution - 0053
    Dallas, Texas 75203, United States
  • Local Institution - 0052
    Dallas, Texas 75234, United States
  • Texas Digestive Disease Consultants - Dallas
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-88520, United States
  • Texas Digestive Disease Consultants - Southlake
    Fort Worth, Texas 76104, United States
  • Local Institution - 0004
    Houston, Texas 77002, United States
  • Local Institution - 0059
    Houston, Texas 77030, United States
  • Local Institution - 0062
    Houston, Texas 77030, United States
  • Local Institution - 0029
    San Antonio, Texas 78215, United States
  • Local Institution - 0012
    San Antonio, Texas 78229, United States
  • Local Institution - 0101
    San Antonio, Texas 78229, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Gastroenterology Associates, PC
    Manassas, Virginia 20110, United States
  • Local Institution - 0069
    Norfolk, Virginia 23502, United States
  • The Gastroenterology Group
    Reston, Virginia 20191, United States
  • Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • Local Institution - 0077
    Richmond, Virginia 23249, United States
  • Local Institution - 0049
    Richmond, Virginia 23298, United States
  • Kurume University Hospital
    Kurume, Fukuoka 8300011, Japan
  • Local Institution - 0056
    Yokohama, Kanagawa 236-0004, Japan
  • Local Institution - 0072
    Kashihara, Nara 6348522, Japan
  • Toranomon Hospital
    Minato, Tokyo 105-8470, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 1600016, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
09

References and documents

Publications

  • Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021 May;104:106335. doi: 10.1016/j.cct.2021.106335. Epub 2021 Feb 28. PubMed 33657443 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Sep 2020, 26 months.

Results were first posted in Sep 2022, 1 year 11 months after primary completion. A results delay was requested in Jul 2021.

Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 26 months is close to that.

Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2018
First posted
Apr 3, 2018
StartActual
Jun 19, 2018
Primary completionActual
Sep 14, 2020
CompletionActual
Aug 17, 2021
Results delay requested
Jul 9, 2021
Results first posted
Sep 9, 2022
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03486899
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Jun 19, 2018
Primary completion
Sep 14, 2020
Completion
Aug 17, 2021
Results posted
Sep 9, 2022
Last update
Sep 9, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegbelfermin

Start the discussion